INGN logo

Inogen, Inc. (INGN) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Inogen, Inc. (INGN), Healthcare sektöründe faaliyet gösteriyor, son olarak 6.55$'dan işlem görüyor ve $178.37M piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 55/100 puan alıyor.

Son analiz: 8 Şub 2026
55/100 AI Puanı PD $178.37M Hacim 70.5K

Inogen, Inc. (INGN) Sağlık ve Boru Hattı Genel Bakışı

CEOKevin R. Smith
Çalışanlar766
MerkezGoleta, CA, US
Halka Arz Yılı2014
SektörHealthcare

Inogen is a medical technology innovator, providing portable oxygen concentrators that enhance the lives of patients with chronic respiratory conditions. With a focus on patient independence and superior technology, Inogen is positioned to capitalize on the growing demand for home healthcare solutions.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 8 Şub 2026

Yatırım Tezi

Inogen presents a notable research candidate due to the increasing prevalence of chronic respiratory diseases and the growing demand for portable oxygen therapy solutions. The company's Inogen One system offers a significant advantage over traditional oxygen tanks, providing patients with greater mobility and independence. While Inogen's current P/E ratio is negative at -5.89 and the profit margin is -7.3%, the company's innovative products and direct-to-patient rental model have the potential to drive future profitability. Key growth catalysts include expanding market penetration in international markets and increasing adoption of POCs among healthcare providers. The company's gross margin of 46.4% indicates a strong potential for profitability as revenue scales.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.15 billion reflects the company's current valuation in the market.
  • Gross margin of 46.4% demonstrates the company's ability to maintain profitability on its core products.
  • Beta of 1.79 indicates higher volatility compared to the overall market.
  • The company operates in the growing market for portable oxygen concentrators, driven by an aging population and increasing prevalence of respiratory diseases.
  • Inogen's direct-to-patient rental model provides recurring revenue and strengthens customer relationships.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative portable oxygen concentrator technology.
  • Direct-to-patient rental model.
  • Strong brand reputation.
  • Established distribution network.

Zayıflıklar

  • Negative profit margin.
  • High beta, indicating higher volatility.
  • Reliance on reimbursement from third-party payors.
  • Limited product diversification.

Katalizörler

  • Ongoing: Expansion of direct-to-patient rental program to new geographic areas.
  • Upcoming: Potential regulatory approvals for new products in international markets.
  • Ongoing: Development and launch of next-generation portable oxygen concentrators with improved features.
  • Ongoing: Strategic partnerships with healthcare providers and insurance companies to expand market reach.

Riskler

  • Potential: Changes in reimbursement policies could negatively impact revenue.
  • Ongoing: Competition from established medical device companies could erode market share.
  • Potential: Technological obsolescence could render existing products less competitive.
  • Ongoing: Economic downturn could reduce demand for oxygen therapy products.
  • Potential: Product recalls or safety concerns could damage the company's reputation.

Büyüme Fırsatları

  • Expanding International Presence: Inogen has the opportunity to expand its market share in international markets, particularly in Europe and Asia, where the demand for portable oxygen concentrators is growing. By establishing strategic partnerships and tailoring its products to meet local regulatory requirements, Inogen can tap into new revenue streams. The global market for respiratory devices is projected to reach $25 billion by 2028, providing a significant opportunity for Inogen to increase its international sales.
  • Direct-to-Patient Rental Model: Inogen's direct-to-patient rental model provides a recurring revenue stream and allows the company to build direct relationships with its customers. By expanding its rental program and offering flexible payment options, Inogen can attract new customers and increase customer retention. This model also provides valuable data on patient usage patterns, which can be used to improve product development and marketing efforts. The market for home healthcare services is expected to grow as the population ages and more patients seek to manage their conditions from the comfort of their homes.
  • Technological Innovation: Inogen can continue to invest in research and development to improve the performance and features of its portable oxygen concentrators. By developing smaller, lighter, and more energy-efficient devices, Inogen can maintain its competitive edge and attract new customers. The company can also explore new technologies such as remote monitoring and telehealth to enhance patient care and improve outcomes. The market for connected medical devices is growing rapidly, providing opportunities for Inogen to integrate its products with other healthcare technologies.
  • Strategic Partnerships: Inogen can form strategic partnerships with healthcare providers, insurance companies, and other organizations to expand its reach and increase its market share. By partnering with hospitals and clinics, Inogen can provide its products to patients who are discharged from the hospital and need ongoing oxygen therapy. By partnering with insurance companies, Inogen can make its products more accessible to patients who have limited financial resources. Strategic partnerships can help Inogen to reduce its marketing costs and increase its brand awareness.
  • Expanding Product Line: Inogen can expand its product line to include other respiratory care devices and accessories. By offering a comprehensive range of products, Inogen can become a one-stop shop for patients with respiratory conditions. The company can also explore new markets such as sleep apnea and asthma, where there is a growing demand for innovative respiratory solutions. Expanding the product line can help Inogen to diversify its revenue streams and reduce its reliance on its core portable oxygen concentrator business.

Fırsatlar

  • Expanding international presence.
  • Increasing adoption of portable oxygen concentrators.
  • Developing new respiratory care devices and accessories.
  • Forming strategic partnerships with healthcare providers and insurance companies.

Tehditler

  • Competition from established medical device companies.
  • Changes in reimbursement policies.
  • Technological obsolescence.
  • Economic downturn.

Rekabet Avantajları

  • Proprietary Technology: Inogen's patented technology for portable oxygen concentrators provides a competitive advantage.
  • Direct-to-Patient Model: The company's direct-to-patient rental model creates a recurring revenue stream and strengthens customer relationships.
  • Brand Recognition: Inogen has established a strong brand reputation for quality and innovation in the oxygen therapy market.
  • Distribution Network: Inogen has a well-established distribution network that allows it to reach patients and healthcare providers across the United States and internationally.

INGN Hakkında

Inogen, Inc. was founded in 2001 with a mission to improve the lives of individuals suffering from chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators (POCs) that provide supplemental oxygen therapy. Its flagship product, the Inogen One, is a lightweight and portable device that allows patients to maintain an active lifestyle while receiving necessary oxygen. Unlike traditional oxygen tanks, the Inogen One concentrates oxygen from the surrounding air, eliminating the need for refills and enhancing patient mobility. In addition to the Inogen One, the company offers the Inogen At Home stationary oxygen concentrator for use in the home, as well as Inogen Tidal Assist Ventilators. Inogen serves patients, physicians, clinicians, and third-party payors both in the United States and internationally. The company also generates revenue through direct rentals of its products to patients. Headquartered in Goleta, California, Inogen continues to innovate in the respiratory care market, focusing on patient-centric solutions and expanding its reach to meet the growing global demand for oxygen therapy.

Ne Yaparlar

  • Develops portable oxygen concentrators (POCs) for patients with chronic respiratory conditions.
  • Manufactures POCs that are lightweight and easy to carry.
  • Markets POCs directly to patients, physicians, and third-party payors.
  • Offers the Inogen One, a portable device that concentrates oxygen from the air.
  • Provides Inogen At Home stationary oxygen concentrators for home use.
  • Rents POCs directly to patients, providing a recurring revenue stream.
  • Sells related accessories for oxygen concentrators.

İş Modeli

  • Direct sales of portable oxygen concentrators to patients, physicians, and clinicians.
  • Rental of oxygen concentrators directly to patients.
  • Sales of accessories related to oxygen concentrators.
  • Reimbursement from third-party payors, such as insurance companies and government healthcare programs.

Sektör Bağlamı

Inogen operates within the medical device industry, specifically focusing on respiratory care. The market for oxygen therapy is driven by the increasing prevalence of chronic respiratory diseases such as COPD and asthma. The industry is characterized by technological innovation, with companies constantly seeking to develop more efficient and user-friendly devices. Inogen competes with companies offering traditional oxygen tanks, as well as other portable oxygen concentrator manufacturers. The global respiratory care devices market is expected to continue to grow, driven by an aging population and increasing awareness of respiratory health issues.

Kilit Müşteriler

  • Patients with chronic respiratory conditions, such as COPD, emphysema, and asthma.
  • Physicians and other clinicians who prescribe oxygen therapy to their patients.
  • Third-party payors, such as insurance companies and government healthcare programs, who reimburse the cost of oxygen therapy.
  • Home healthcare providers who provide oxygen therapy to patients in their homes.
AI Güveni: 71% Güncellendi: 8 Şub 2026

Finansallar

Grafik & Bilgi

Inogen, Inc. (INGN) hisse senedi fiyatı: $6.55 (+0.01, +0.16%)

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

INGN için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

INGN için Wall Street fiyat hedefi analizi.

MoonshotScore

55/100

Bu puan ne anlama geliyor?

MoonshotScore, INGN'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

INGN Hakkında Sıkça Sorulan Sorular

INGN için değerlendirilmesi gereken temel faktörler nelerdir?

Inogen, Inc. (INGN) şu anda yapay zeka skoru 55/100, orta puanı gösteriyor. Temel güçlü yan: Innovative portable oxygen concentrator technology.. İzlenmesi gereken birincil risk: Potential: Changes in reimbursement policies could negatively impact revenue.. Bu bir finansal tavsiye değildir.

INGN MoonshotScore'u nedir?

INGN şu anda MoonshotScore'da 55/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

INGN verileri ne sıklıkla güncellenir?

INGN fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler INGN hakkında ne diyor?

INGN için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

INGN'a yatırım yapmanın riskleri nelerdir?

INGN için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Changes in reimbursement policies could negatively impact revenue.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

INGN'ın P/E oranı nedir?

INGN için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için INGN'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

INGN aşırı değerli mi, yoksa düşük değerli mi?

Inogen, Inc. (INGN)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

INGN'ın temettü verimi nedir?

Inogen, Inc. (INGN) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Fiyat itibarıyla Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Financial data may be subject to change.
  • Market conditions and industry trends can impact company performance.
  • This analysis is based on available information and does not constitute financial advice.
Veri Kaynakları

Popüler Hisseler